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Abstract 
Review on t(3;8)(p25;q24), with data on clinics 
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Clinics and pathology 
Disease 
Blastic plasmacytoid dendritic cell neoplasm 
(BPDCN)  
BPDCN has been known with various names, 
including agranular CD4+ natural killer (NK) 
leukemia, CD4+/CD56+ hematodermic neoplasm, 
and blastic NK lymphoma. BPDCN malignant cells 
are derived from the precursors of plasmacytoid 
dendritic cells. It most commonly involves the skin. 
BPDCN is an aggressive neoplasm. BPDCN is often 
associated with a complex karyotype (review in 
Meloni-Ehrig 2017). 
Epidemiology 
In a series of 41 patients with BPDCN, five had a 
MYC rearrangement confirmed by FISH, one had a 
t(X;8)(q24;q24), one had a t(3;8)(p25;q24), two had 
a t(6;8)(p21;q24) MYC/SUPT3H, and one had a 
t(8;14)(q24.1;q32) (Boddu et al., 2018). 
Clinics 
The patient with a t(3;8)(p25;q24) was a 66 year-old 
male patient with skin, lymph nodes and central 
nervous system involvement. He was alive and well 
12 months+ after diagnosis. 
Cytogenetics 
The karyotype was complex. 
Genes involved and 
proteins 
Note  
The partner gene of MYC is unknown.   
MYC 
Location 
8q24.21  
DNA/RNA 
MYC is composed of three exons spanning over 4 
kb.   
Protein 
MYC is expressed in almost all proliferating cells. It 
is located predominantly in the nucleus. MYC is a 
transcriptional regulator, capable to induce or 
repress the expression of thousands genes. MYC is 
deregulated in cancer by several different 
mechanisms: chromosomal translocations, 
amplifications, point mutations, epigenetic 
reprogramming, enhanced translation and increased 
protein stability (review in Mohamed, 2017).  
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